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Abstract
Aims: To test the efficacy of ‘MiQuit’, a tailored, self-help, text message stop smoking
programme for pregnancy, as an adjunct to usual care (UC) for smoking cessation in
pregnancy.
Design: Multicentre, open, two-arm, parallel-group, superiority randomised controlled
trial (RCT) and a trial sequential analysis (TSA) meta-analysis combining trial findings with
two previous ones.
Setting: Twenty-four English hospital antenatal clinics.
Participants: A total of 1002 pregnant women who were ≥16 years old, were ≤25 weeks
gestation and smoked ≥1 daily cigarette and accepted information on cessation with no
requirement to set quit dates.
Interventions: UC or UC plus ‘MiQuit’: 12 weeks of tailored, smoking cessation text
messages focussed on inducing and aiding cessation.
Measurements: Primary outcome: biochemically validated cessation between 4 weeks
after randomisation and late pregnancy. Secondary outcomes: shorter and non-validated
abstinence periods, pregnancy outcomes and incremental cost-effectiveness ratios.
Findings: RCT: cessation was 5.19% (26/501) and 4.59% (23/501) in MiQuit and UC
groups (adjusted odds ratio [adj OR] for quitting with MiQuit versus UC, 95% CI = 1.15
[0.65–2.04]); other abstinence findings were similar, with higher point estimates. Primary
outcome ascertainment was 61.7% (309) and 67.3% (337) in MiQuit and UC groups with
71.1% (54/76) and 69.5% (41/59) abstinence validation rates, respectively. Pregnancy
outcomes were similar and the incremental cost per quality-adjusted life year was −
£1118 (95% CI = −£4806–£1911). More MiQuit group women reported making at least
one quit attempt (adj OR [95% CI]) for making an attempt, 1.50 (1.07–2.09). TSA meta-
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analysis: this found no significant difference in prolonged abstinence between MiQuit
and UC (pooled OR = 1.49, adjusted 95% CI = 0.62–3.60).
Conclusions: Irrespective of whether they want to try quitting, when offered a tailored,
self-help, text message stop smoking programme for pregnancy (MiQuit) as an adjunct to
usual care, pregnant women are not more likely to stop smoking until childbirth but they
report more attempts at stopping smoking.
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INTRODUCTION
Smoking in pregnancy is strongly associated with increased risks of
miscarriage, stillbirth, prematurity, low birthweight, perinatal morbid-
ity and mortality, neo-natal and sudden infant death [1], poorer infant
cognition and adverse infant behavioural outcomes [2,3]. In high
income countries, 11% to 25% of pregnant women smoke [4] and
rates are increasing in developing ones [5]. In England, the highest
rates are seen among younger and socially disadvantaged women [6].
Smoking-attributable annual United Kingdom (UK) maternal and infant
health care costs were estimated as £87.5 million in 2010 [7] and the
extra healthcare cost, generated by each child born to women who
smoked in pregnancy until age 5, is estimated as £222 (2015 prices)
[8]. After conception, around half of women who smoke try quitting
[9] and many want help [10], but few interventions can assist them.
Behavioural support has a strong evidence base [11] and many
women use nicotine replacement therapy (NRT) [12–14], which may
be less effective in pregnancy [15]. Financial incentives contingent on
cessation are effective but infrequently provided [16].
Self-help behavioural support for smoking cessation in pregnancy
increases the odds of cessation (OR = 1.83, 95% CI = 1.23–2.73) [17].
Self-help consists of structured programmes that develop quitting
skills without health professional involvement [17] and can be deliv-
ered digitally, as text messages [18]. Text message cessation support
is effective for non-pregnant people motivated to make a quit attempt
[19–21] and is likely to work in pregnancy. However, generic
programmes for non-pregnant people are not likely to be effective for
pregnant women because these effectively ignore women’s gestation
and their desire to protect the foetus, which are both key cessation
motivations in pregnancy [9]. Generic programmes also typically
include recommendations on exercise and avoiding weight gain, which
are inappropriate in pregnancy. Behavioural support tailored to users’
contexts enhances the likelihood of this working [22], therefore, text
support that is relevant in pregnancy and builds on pregnant women’s
motivations for quitting would be expected to engender enthusiastic
engagement and be more likely to work.
We developed a tailored, self-help, text message stop smoking
programme for pregnancy called MiQuit. In a feasibility randomised
controlled trial (RCT), in MiQuit and control groups, validated 7-day
point prevalence abstinence at 12 weeks was 12.5% and 7.8%,
respectively, (OR = 1.68, 95% CI = 0.90–3.16) [23] and in a multi-
centre pilot RCT, prolonged abstinence from smoking, validated in late
pregnancy was 5.4% (MiQuit) and 2.0% (control) (OR = 2.70, 95% CI =
0.93–9.35) [24]. Here, we report a comprehensive evaluation of
MiQuit, including a third RCT with economic analysis and a trial
sequential analysis (TSA) [25] of all MiQuit trials.
METHODS
This was an individually randomised, multicentre, parallel group, out-
come assessor-blind, superiority RCT, with participants recruited
from 24 English National Health Service (NHS) hospital antenatal
clinics between December 2017 and February 2019. Further details
are in the published protocol [26]. Participants were eligible if they
were not already using text message support, smoked at least one
daily cigarette (five before pregnancy), were 16 years or older, up to
25 weeks gestation and able to receive and understand English text
messages. During antenatal visits, potential participants were
identified, given participant information sheets and, where possible,
consented. Alternatively, consent was obtained verbally later by
telephone.
Baseline data were collected and participants were randomised in
a 1:1 ratio using York Clinical Trials Unit’s online randomisation plat-
form. Randomisation used computer generated blocks of randomly
varying size (4, 6 and 8 allocations), stratified by gestation at baseline
(<16 weeks or ≥16 weeks). Following randomisation, researchers
posted information packs to participants, which gave details of their




Participants could use any smoking cessation information, advice or
support available to them within usual NHS antenatal care and were
given the ‘Baby on the way, quit today’ smoking cessation booklet
(see Supporting Information).
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Intervention
This started 2 days after enrolment and consisted of UC plus the 12-
week MiQuit programme. Full details of MiQuit are published else-
where [23,27]. MiQuit was designed for any pregnant woman who
smokes. In those who lack motivation and are not ready to try stop-
ping, it aims to encourage quit attempts and to ‘induct’ women into
quitting. Women who want to try stopping are encouraged to set a
quit date. Messages are personalised using 14 recipient characteris-
tics, such as name, week of gestation, partner’s smoking [23,27], nico-
tine dependence [28,29] and, for those who set them, quit dates.
Messages are more frequent early in the programme and the number
sent varies between users; in the pilot study, the average number sent
to each participant was 84. Messages include information on fetal
development, motivation for and preparing to stop, managing cravings
and withdrawal, combatting smoking ‘triggers’ and preventing lapses.
Users can vary text frequency by texting MORE or LESS, or end mes-
sages with STOP. After texting HELP, they receive ‘on-demand’ sup-
port. Texting SLIP provides tips for combatting urges and QUIZ
initiates a texted trivia game to distract from urges.
At baseline, we asked about education, ethnicity, gestation; pre-
pregnancy and current daily cigarettes smoked; nicotine dependence
[28]; strength and frequency of smoking urges [26]; intention to quit;
whether a quit date was set; number of pregnancies beyond
24 weeks; and partner’s or significant other’s smoking and health sta-
tus (EQ-5D-5L) [30].
Four weeks after randomisation, masked to study allocation, a
researcher phoned participants to ask about smoking in the previous
week and repeated EQ-5D items; if no contact occurred, we texted
and emailed web links to online questionnaires or mailed paper copies.
At 36 weeks gestation, a researcher called again and initially, when still
masked, asked about smoking in the past week and since the earlier
call; quit attempts; use of cessation support; and EQ-5D. If participants
reported 7-day smoking abstinence, we arranged hospital or home
visits to collect exhaled-breath carbon monoxide (CO) readings and/or
saliva samples for validation. Alternatively, we posted ‘self-donation’
saliva collection packs with instructions. Before providing saliva,
women were asked if they had smoked and/or used NRT or e-
cigarettes in the previous week. We offered £5 shopping vouchers for
provision of complete data at each contact and, if this was provided for
all 3 contacts were, an additional £10 one was offered (£45 maximum).
Additionally, we offered a £30 voucher following successful validation
visits. We sought pregnancy outcome data from hospital records.
Outcomes
The primary outcome was self-reported prolonged abstinence
between 4 weeks post-randomisation and late pregnancy, at around
36 weeks gestation, with biochemical validation of self-reported
7-day abstinence at the later time point. Biochemical validation was
based on an exhaled CO reading with a cut-point of ≤9 p.p.m, and/or
saliva cotinine (cut-point ≤10 ng/mL) or anabasine (cut-point
≤0.2 ng/mL) readings [31]. Participants for whom there was no self-
reported abstinence data at late pregnancy or whose abstinence
reports remained unvalidated were assumed to be smoking
(Supporting information Figure S1). There were six further abstinence
outcomes (Supporting information Table S1). Other cessation out-
comes collected at late pregnancy included the number of quit
attempts lasting >24 hours, daily cigarette consumption and use of
NHS stop smoking support. Pregnancy outcomes included miscar-
riage, stillbirth, birthweight, gestational age at birth and maternal/
infant hospital/intensive care unit (ICU) admissions. For economic
analyses we monitored additional costs required to deliver MiQuit.
Statistical analysis
Sample size
We estimated the size of this RCT (called ‘MiQuit3’) such that, when
combined in a TSA with findings from MiQuit feasibility [23] and pilot
[24] RCTs, the optimal information size would be reached [25]. The
MiQuit pilot [24] and MiQuit3 trials were very similar in design and
the only major difference was that the pilot had a smaller sample size
(n = 407). The MiQuit feasibility RCT [23] was smaller still (n = 207)
with a very similar design, but assessed the primary endpoint, vali-
dated cessation at 12 weeks post randomisation, rather than the end
of pregnancy, and only minor changes were made to MiQuit between
the feasibility and other trials. We anticipated event rates, as in the
MiQuit pilot RCT [24], of prolonged abstinence from smoking at
4 weeks after enrolment until 36 weeks’ gestation as 5.4% in the
MiQuit arm versus 2.0% for UC (3.4% absolute difference). For 90%
power in a two-sided test of size 5%, an optimal information size,
unadjusted for diversity (D2 = 0%), of 1296 participants was required.
Because MiQuit feasibility [23] and pilot [24] RCTs had primary out-
come data on 605 participants, MiQuit3 needed to recruit a further
692 (346 per group). Trial recruitment was very rapid, therefore, three
months after starting, we re-visited the information size estimate to
investigate whether a larger MiQuit3 sample size would be sufficient
to detect an overall smaller intervention effect in the TSA. With
funders’ permission we increased the sample size of MiQuit3 to 1000
(500 per group); this sample size could detect a modestly smaller
treatment effect and was consistent with available resources. We did
not attempt to recruit an even larger sample because modelling of
changes to the TSA-based sample size estimate showed that, with
even quite large further increases in sample size (i.e. >1000), the study
would not have much more power to detect even smaller treatment
effects. Further details of sample size estimation and how trials’ data
were combined are published elsewhere [32].
Main RCT analysis
All within-trial outcomes were analysed once at the trial’s conclusion
following a TSC approved statistical analysis plan. Analyses were
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undertaken in Stata v16.0 following intention-to-treat principles, with
participants being analysed as part of the group to which they were
allocated, regardless of subsequent adherence to the allocated
treatment.
Baseline data were summarised descriptively by group. The pri-
mary outcome and secondary abstinence outcomes were analysed
using Firth logistic regression models, with allocation, weeks’ gesta-
tion at baseline (the stratification factor) and recruitment site included
as fixed effects. ORs with 95% profile penalised likelihood CIs and
estimated risk differences with Wald 95% CIs were obtained from the
fitted models. The primary analysis was an intention to treat analysis
with those lost to follow up assumed to be still smoking (i.e. outcome
data were assumed to be missing not at random). It was anticipated
that there could be differences in baseline ‘risk’ of abstinence across
sites (e.g. because of different support being available, different
patient demographics etc.). To model this outcome heterogeneity, we
used fixed effects for site (as opposed to fitting random intercepts for
sites) for a couple of reasons; (i) to be consistent with the approach
used in the previous MiQuit trials to facilitate synthesis; (ii) because of
concerns about obtaining a reasonable estimate of the between-site
variance with a relatively small number of sites. Several sensitivity
analyses of the primary outcome were undertaken to investigate the
possible influence of additional baseline covariates (partner’s smoking
status, strength of nicotine dependence and educational attainment),
missing data assumptions (via imputation methods) and the choice of
analysis model. Complier Average Causal Effect (CACE) analyses were
undertaken using an instrumental variable approach to explore the
impact of compliance (time they spent on the programme [>4 weeks
vs ≤4 weeks] and self-reported receipt of texts) on the primary
outcome.
Binary pregnancy outcomes (infant mortality, hospital/ICU admis-
sions and pre-term birth) were analysed using Firth logistic regression
models adjusting for allocation, recruitment site, weeks’ gestation at
baseline, strength of nicotine dependence and maternal education.
Continuous pregnancy outcomes (birthweight and gestational age)
were analysed using linear regression of the untransformed response
on the same set of covariates outlined above. Birthweight and infant
ICU admissions were analysed at the level of the participating mother
(as opposed to the individual infant for multiple births).
TSA meta-analysis
A prospective cumulative meta-analysis approach based on a random
effects model was used to pool the trial results with those from the
two previous trials [23,24]. To overcome issues related to multiple
testing within the cumulative meta-analysis, a TSA was also con-
ducted to assess whether the cumulative Z curve crosses the TSA
monitoring boundary and to estimate an adjusted 95% CI for the
pooled OR. An inner wedge was applied. Inferences concerning the
effectiveness of MiQuit were based on the comparison of this pooled
OR and its associated cumulative Z score with pre-determined trial
sequential monitoring boundaries. The analyses were conducted using
the TSA program (developed by The Copenhagen Trial Unit, Center
for Clinical Intervention Research, Denmark). The main TSA analysis
investigated the confidence we could have in findings with respect to
the anticipated 3.4% difference between MiQuit and UC, and a sensi-
tivity analysis investigated the likelihood that a smaller 2% difference
might be present. However, it is worth noting that, because of the
substantial health gains that accrue from stopping smoking, even
smaller differences than this would be considered clinically effective if
they could be robustly detected [33].
Economics
Because both arms were eligible to receive the same cessation sup-
port from NHS SSS, the costs of providing this were assumed to be
the same and were excluded from the analysis; therefore, the only
additional costs were those attributable to the MiQuit3 intervention.
These included the cost per text message sent and the monthly cost
of providing a virtual reply number. The ‘per participant’ cost was
estimated by dividing the total cost by the number of participants in
the experimental arm. All costs were in 2018 to 2019 prices. The
‘per-participant’ cost and quit rates from MiQuit3 trial arms were
inputted to the Economics of Smoking in Pregnancy (ESIP) model
[34,35], which performed a cost-utility analysis from a NHS perspec-
tive over both the maternal and infant lifetimes, estimating an incre-
mental cost per additional quality-adjusted life year (QALY) ratio and
return on investment (defined as savings in healthcare expenditure).
ESIP includes costs and health outcomes associated with several long
term health conditions as well as pregnancy morbidities that have
been associated with smoking [34,35]. Costs and outcomes were
discounted at 3.5%, and a probabilistic sensitivity analysis was per-
formed to indicate uncertainty [36,37]. EQ-5D was collected because
the ESIP was still in development alongside the trial. However,
because the ESIP model was complete and validated before the trial
analysis was undertaken, ESIP was used in preference to the trial EQ-
5D data.
FINDINGS
Between December 2017 and February 2019, 3964 pregnant smokers
at 25 English antenatal clinics were assessed for eligibility. Of these,
1002 (25.3%) were recruited to the study, with 501 participants being
randomised to each arm. Twenty-four sites recruited at least one
patient, with sites recruiting a median of 34 patients (IQR = 12.5–49).
Figure 1 shows participant flow through the study. Of the 1002
participants, 739 (73.8%) were followed up at 4 weeks and
646 (64.5%) in late pregnancy. Pregnancy outcomes were available
for 930 (92.8%) participants. Thirty-eight (3.8%) participants fully
withdrew (withdrawal of consent n = 24, fetal death n = 14), 21 (4.2%)
in the MiQuit group and 17 (3.4%) in the control group. Of the 38 par-
ticipants who fully withdrew, 5 provided data at 4 weeks, but none
did in late pregnancy. A total of 17 of 21 withdrawals were before
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completion of the MiQuit programme. Twenty-eight participants who
sent a STOP text were considered to have withdrawn from the
MiQuit programme, but not from the trial. Therefore, 456 (91.0%) par-
ticipants allocated to MiQuit remained on the programme for the full
87-day duration.
Baseline data
Participants’ characteristics were similar in both groups and are
summarised in Table 1. Participants were predominantly white, had an
average age of 27.3 years and average gestation of 15.0 weeks at
F I GU R E 1 Flow diagram. *Two participants also provided a saliva sample, but there was insufficient sample volume to obtain cotinine and
anabasine readings. **Pregnancy outcomes data available for one participant who fully withdrew
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T AB L E 1 Key baseline characteristics by allocation
Characteristic
Randomised treatment group
MiQuit (n = 501) Control (n = 501) Total (n = 1002)
Age (y)
Mean (SD) 27.1 (5.6) 27.5 (5.7) 27.3 (5.6)
Median (Q1, Q3) 26.4 (22.7, 31.0) 26.9 (23.2, 31.5) 26.7 (22.9, 31.2)
Min, max 16.7, 43.4 16.4, 43.2 16.4, 43.4
Ethnicity, n (%)
White 469 (93.6) 476 (95.0) 945 (94.3)
Indian 2 (0.4) 2 (0.4) 4 (0.4)
Pakistani 5 (1.0) 2 (0.4) 7 (0.7)
Black Caribbean 3 (0.6) 2 (0.4) 5 (0.5)
Black African 2 (0.4) 0 (0.0) 2 (0.2)
Other Asian (non-Chinese) 0 (0.0) 1 (0.2) 1 (0.1)
Mixed race 18 (3.6) 16 (3.2) 34 (3.4)
Missing 2 (0.4) 2 (0.4) 4 (0.4)
Gestation at baseline (weeks)
Mean (SD) 14.9 (4.0) 15.0 (3.8) 15.0 (3.9)
Median (Q1, Q3) 13.1 (12.3, 19.3) 13.4 (12.3, 19.3) 13.3 (12.3, 19.3)
Min, max 6.0, 24.7 6.0, 24.9 6.0, 24.9
Previous pregnancies beyond 24 weeks
Mean (SD) 1.3 (1.4) 1.4 (1.4) 1.3 (1.4)
Median (Q1, Q3) 1.0 (0.0, 2.0) 1.0 (0.0, 2.0) 1.0 (0.0, 2.0)
Min, max 0.0, 7.0 0.0, 7.0 0.0, 7.0
Previous pregnancies beyond 24 weeks, n (%)
Zero 177 (35.3) 162 (32.3) 339 (33.8)
One or more 324 (64.7) 339 (67.7) 663 (66.2)
Partner’s smoking, n (%)
Single 85 (17.0) 81 (16.2) 166 (16.6)
Partner a non-smoker 90 (18.0) 103 (20.6) 193 (19.3)
Partner a smoker 326 (65.1) 317 (63.3) 643 (64.2)
Cigarettes/day before pregnancy
Mean (SD) 17.2 (9.0) 16.7 (6.6) 16.9 (7.9)
Median (Q1, Q3) 15.0 (10.0, 20.0) 15.0 (10.0, 20.0) 15.0 (10.0, 20.0)
Min, max 5.0, 100.0 5.0, 40.0 5.0, 100.0
Cigarettes/day now
Mean (SD) 8.6 (5.5) 8.9 (5.5) 8.8 (5.5)
Median (Q1, Q3) 8.0 (5.0, 10.0) 8.0 (5.0, 10.0) 8.0 (5.0, 10.0)
Min, max 1.0, 40.0 1.0, 40.0 1.0, 40.0
Time from waking to first cigarette, n (%)
Within 5 min 149 (29.7) 148 (29.5) 297 (29.6)
6–30 min 160 (31.9) 174 (34.7) 334 (33.3)
31–59 min 75 (15.0) 75 (15.0) 150 (15.0)
1–2 h 68 (13.6) 71 (14.2) 139 (13.9)
More than 2 h 49 (9.8) 33 (6.6) 82 (8.2)
Heaviness of Smoking Indexa
Mean (SD) 1.9 (1.4) 2.0 (1.4) 2.0 (1.4)
(Continues)
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T AB L E 1 (Continued)
Characteristic
Randomised treatment group
MiQuit (n = 501) Control (n = 501) Total (n = 1002)
Median (Q1, Q3) 2.0 (1.0, 3.0) 2.0 (1.0, 3.0) 2.0 (1.0, 3.0)
Min, max 0.0, 6.0 0.0, 6.0 0.0, 6.0
Strength of addictionb, n (%)
Low addiction 306 (61.1) 319 (63.7) 625 (62.4)
Moderate addiction 188 (37.5) 176 (35.1) 364 (36.3)
High addiction 7 (1.4) 6 (1.2) 13 (1.3)
Education, n (%)
No formal qualifications 78 (15.6) 76 (15.2) 154 (15.4)
GCSEs (or equivalent) 266 (53.1) 265 (52.9) 531 (53.0)
A levels (or equivalent) 116 (23.2) 109 (21.8) 225 (22.5)
Degree or higher 37 (7.4) 46 (9.2) 83 (8.3)
Missing 4 (0.8) 5 (1.0) 9 (0.9)
Urges to smoke in past 24 hours, n (%)
Not at all 14 (2.8) 10 (2.0) 24 (2.4)
A little of the time 116 (23.2) 115 (23.0) 231 (23.1)
Some of the time 209 (41.7) 222 (44.3) 431 (43.0)
A lot of the time 98 (19.6) 99 (19.8) 197 (19.7)
Almost all of the time 38 (7.6) 36 (7.2) 74 (7.4)
All of the time 26 (5.2) 19 (3.8) 45 (4.5)
Strength of urges in past 24 hours, n (%)
No urges 7 (1.4) 5 (1.0) 12 (1.2)
Slight 134 (26.7) 117 (23.4) 251 (25.0)
Moderate 185 (36.9) 222 (44.3) 407 (40.6)
Strong 107 (21.4) 95 (19.0) 202 (20.2)
Very strong 35 (7.0) 36 (7.2) 71 (7.1)
Extremely strong 10 (2.0) 10 (2.0) 20 (2.0)
Missing 23 (4.6) 16 (3.2) 39 (3.9)
Seriously planning to quit? n (%)
Within next 2 weeks 126 (25.1) 127 (25.3) 253 (25.2)
Within next 30 days 137 (27.3) 121 (24.2) 258 (25.7)
Within next 3 months 190 (37.9) 208 (41.5) 398 (39.7)
No 46 (9.2) 44 (8.8) 90 (9.0)
Missing 2 (0.4) 1 (0.2) 3 (0.3)
Longest previous quit attempt, n (%)
Quit not attempted 125 (25.0) 112 (22.4) 237 (23.7)
Less than 2 weeks 97 (19.4) 114 (22.8) 211 (21.1)
2–5 weeks 77 (15.4) 62 (12.4) 139 (13.9)
6–11 weeks 29 (5.8) 43 (8.6) 72 (7.2)
12 weeks or more 173 (34.5) 170 (33.9) 343 (34.2)
How important is it to you to stop smoking at least until your baby is born? n (%)
Not at all 4 (0.8) 3 (0.6) 7 (0.7)
A little 15 (3.0) 17 (3.4) 32 (3.2)
Moderately 62 (12.4) 64 (12.8) 126 (12.6)
Very much 174 (34.7) 152 (30.3) 326 (32.5)
(Continues)
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enrolment. Self-reported daily cigarette consumption was generally
lower at the time of the baseline visit than before pregnancy, with
856 (85.4%) participants reporting lower consumption at enrolment
than before pregnancy. Strength of nicotine dependence was gener-
ally low to moderate, with 989 (98.7%) scoring ≤4 on the Heaviness
of Smoking Index [28]. The 646 participants who were followed up at
late pregnancy had reasonably similar characteristics, with educational
attainment being a possible exception (see Supporting information
Table S2).
Abstinence outcomes
Of the 1002 participants, 356 (35.5%) were lost to follow up in late
pregnancy: 192 (38.3%) in the MiQuit group and 164 (32.7%) in the
control group. Of the 646 (64.5%) participants followed up in late
pregnancy, 135 (20.9%) reported 7-day abstinence and, of these
95 (70.4%) underwent biochemical validation; six had CO readings
only, 59 had CO readings and saliva samples, and 30 had saliva only.
Details of the biochemical validation are in Supporting information
Figure S2. A total of 101 (15.6%) of 135 women who reported 7-day
abstinence also reported smoking no more than five cigarettes
between 4 weeks post-randomisation and the later follow up point,
54 in the MiQuit group and 47 in the control group. Thirty-two of
these participants did not provide either a CO reading or a saliva sam-
ple. Hence, 69 participants who reported both prolonged and 7-day
abstinence underwent some form of validation: 66.7% (36/54) in the
MiQuit group and 70.2% (33/47) in the control group. Figure 2 details
primary outcome ascertainment.
Forty-nine (4.9%) participants had values below relevant valida-
tion test thresholds and were classed as abstinent, 26 (5.19%) were in
the MiQuit and 23 (4.59%) in the control group. The adjusted OR (adj
OR) was 1.15 (95% CI = 0.65–2.04) and, the adjusted difference in
the proportions was 0.76% (−2.38%–3.89%) (Table 2). Treatment
effect estimates for abstinence outcomes 2 to 7 are broadly similar to
the primary outcome estimate, however, those reflecting shorter
abstinence periods (outcomes 3–7) were more favourable toward
MiQuit, albeit with reasonably wide CIs that easily included OR = 1
(Table 2).
Further adjustment for partner’s smoking status, nicotine depen-
dence and educational attainment did not materially change the
estimates, although there was some evidence that these adjust-
ments led to slightly improved model fit (Supporting information
Table S3). The proportion of participants who were validated as
abstinent, out of those who self-reported abstinence (either pro-
longed or 7-day) was similar in both groups. Of the participants in
the MiQuit group who reported prolonged abstinence, 48.1% were
validated as abstinent, compared with 48.9% in the control group.
Of the participants in the MiQuit group who reported 7-day absti-
nence, 50.0% were validated as abstinent, compared with 49.2% in
the control group.
Missing outcome data (and missing values of variables included in
the imputation model) were imputed using multiple imputations by
chained equations, assuming these data were missing at random
(MAR). The primary analysis model was fitted to each of the imputed
datasets, with the point estimates being combined using Rubin’s rules
and profile penalised likelihood CIs being obtained following the
approach described by Heinze et al. [38,39]. This gave an OR of 1.14
(95% CI = 0.66–1.98) and similar inference to the primary analysis.
Supporting information Tables S4–S9 and Supporting information
Figures S7–S10 present findings from analyses exploring variation in
the missing data assumptions, with full details of sensitivity analyses
and alternative estimands, provided in the supplement. We also
explored the sensitivity of the results to departures from MAR less
extreme than missing = smoking and, allowed the missingness mecha-
nism to vary by randomised group [40]. Findings suggested that both
primary and imputed data analyses were reasonably robust, as rela-
tively implausible assumptions about the missing data mechanisms is
required for the primary outcome conclusions to be altered (Table 3
and Supporting information Figure S10).
T AB L E 1 (Continued)
Characteristic
Randomised treatment group
MiQuit (n = 501) Control (n = 501) Total (n = 1002)
Extremely 246 (49.1) 264 (52.7) 510 (50.9)
Missing 0 (0.0) 1 (0.2) 1 (0.1)
How confident are you that you can stop smoking until your baby is born? n (%)
Not at all 34 (6.8) 30 (6.0) 64 (6.4)
A little 97 (19.4) 90 (18.0) 187 (18.7)
Moderately 189 (37.7) 198 (39.5) 387 (38.6)
Very much 119 (23.8) 124 (24.8) 243 (24.3)
Extremely 62 (12.4) 58 (11.6) 120 (12.0)
Missing 0 (0.0) 1 (0.2) 1 (0.1)
aHeaviness of Smoking Index (HSI) based on number of daily cigarettes at time of the baseline visit and time from waking to first cigarette.
bBased on HSI: low addiction if HSI = 0, 1 or 2, moderate addiction if HSI = 3 or 4, high addiction if HSI = 5 or 6.
GCSE = General Certificate of Secondary Education; A Levels = Advanced Levels.
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TSA
A meta-analysis of the three MiQuit trials found no significant dif-
ference in the effectiveness of MiQuit compared with UC (pooled
OR = 1.49, 95% adjusted-CI = 0.62–3.60, P = 0.12), with low levels
of heterogeneity (I2 = 10%) and diversity (D2 = 17%, 95% CI =
0%–64%). Because of the estimated diversity, the diversity-
corrected optimal information size was increased from 1296 to
1555 participants. The TSA for this analysis demonstrates that the
diversity-adjusted optimal information size was reached, but the
monitoring boundary for superiority had not been crossed. How-
ever, the inner wedge had been crossed (Supporting information
Figure S3), thereby indicating evidence of futility, such that further
trials of this intervention may not be required. In the sensitivity
analysis, where a smaller absolute difference of 2% was anticipated
between the intervention groups, the diversity-adjusted optimal
information size was 3669. The cumulative Z-statistic did not reach
the optimal information size and had not crossed the trial
sequential monitoring boundary; thereby indicating that further tri-
als are required before a firm conclusion regarding the effective-
ness of the intervention can be concluded (Supporting information
Figure S4).
Use of stop-smoking services and strategies
Table 4 summarises participants’ use of stop smoking support as
reported in late pregnancy. Of 646 participants followed up at late
pregnancy, 509 (78.8%) indicated that they had either used a form of
cessation support or talked to a health professional about stopping
smoking (251 in the MiQuit group and 258 in the control group) and
99 (15.3%) indicated that they had not used any.
F I GU R E 2 Flow diagram showing
ascertainment of primary abstinence
outcome
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Pregnancy outcomes
Pregnancy outcomes were available for 930 (92.8%) participants
(922 single births and 8 twin births). There were 911 live single
births, 8 live twin births (hence, 927 live infants born), 8 miscar-
riages and 3 stillbirths. Of the 72 participants for whom no
pregnancy outcome data were available, 13 had fetal deaths;
24 withdrew consent, including for provision of pregnancy out-
comes and for the remaining 35 these data were missing without
explanation. The timing of the 13 fetal deaths were unknown,
meaning these cannot be classed as either miscarriages or still-
births. However, these fetal deaths are included as part of the fetal
mortality outcome reported below. Pregnancy outcomes data are
summarised in the Supporting information (Supporting information
Tables S10–S12).
The adj ORs for the risk of miscarriage, stillbirth and fetal mortal-
ity in the MiQuit group compared with control were 0.32 (95% CI =
0.06–1.20), 0.25 (95% CI = 0.01–1.95) and 0.54 (95% CI = 0.23–1.21)
respectively (Table 5). There is little evidence to support the hypothe-
sis that the MiQuit programme influences the likelihood of maternal
hospital admissions (adj OR = 1.07, 95% CI = 0.44–2.63), infant ICU
admissions (adjusted OR 1.10, 95% CI = 0.70–1.73), or pre-term births
(adjusted OR 0.86, 95% CI = 0.58–1.27). Findings were similar when
gestational age at birth was treated as a continuous outcome
(adjusted difference 0.12 weeks, 95% CI = −0.16–0.40). There was
also little evidence to suggest MiQuit has any substantial effect on
birthweight (adjusted difference 0.05 kg, 95% CI = −0.03–0.12)
(Tables 6 and 7).
Non–abstinence smoking outcomes
Among participants who provided data at the late pregnancy follow
up, those in the MiQuit group reported smoking slightly fewer daily
cigarettes than those in the control group (mean [SD] 4.0 [3.9] and
4.9 [5.0]) for MiQuit and control groups, respectively (Supporting
information Table S13). Additionally, MiQuit group women were
more likely to report having made at least one quit attempt lasting
more than 24 hours during the study; 239 (78.9%) of the MiQuit
group who responded to this item reported at least one quit attempt,
compared with 230 (71.0%) in the control group, adj OR = 1.50 (95%
CI = 1.07–2.09).
Economics
The incremental cost of the MiQuit intervention was £3.96 per
participant; Table 4 shows that use of other cessation support was
very similar in trial groups, therefore, the assumption that costs of
providing this to each group would also be similar appears
reasonable. Using a lifetime horizon for ESIP analyses, for combined
maternal and offspring outcomes, the incremental cost per QALY
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On investment was £2.11 in healthcare savings for every pound
spent on MiQuit by the NHS, (95% CI = −£7.92–£14.98). Supporting
information Figures S5 and S6 show the cost effectiveness accept-
ability curve and the cost effectiveness plane.
DISCUSSION
This trial provides little evidence that ‘MiQuit’, a text message, self-
help support programme offered to pregnant women who expressed
T AB L E 4 Use of smoking cessation support
Service/technology
Randomised treatment group
MiQuit (n = 309) Control (n = 337) Total (n = 646)
Talked to GP/nurse about quitting, n (%) 58 (18.8) 63 (18.7) 121 (18.7)
Talked to midwife about quitting, n (%) 177 (57.3) 187 (55.5) 364 (56.3)
Text message support in addition to MiQuit, n (%) 27 (8.7) 14 (4.2) 41 (6.3)
Attended individual NHS stop smoking service
session, n (%)
37 (12.0) 35 (10.4) 72 (11.1)
Attended group NHS stop smoking service
session n (%)
3 (1.0) 4 (1.2) 7 (1.1)
Used nicotine replacement therapy, n (%) 80 (25.9) 70 (20.8) 150 (23.2)
Called stop smoking telephone helpline, n (%) 4 (1.3) 4 (1.2) 8 (1.2)
Used e-cigarettes, n (%) 130 (42.1) 125 (37.1) 255 (39.5)
Visited stop smoking website
(e.g. NHS smokefree), n (%)
43 (13.9) 35 (10.4) 78 (12.1)
Used stop smoking mobile phone app, n (%) 23 (7.4) 12 (3.6) 35 (5.4)
Missing stop smoking service/technology
usage data, n (%)
16 (5.2) 22 (6.5) 38 (5.9)
T AB L E 3 Sensitivity of the primary analysis to variation assumptions used to impute missing primary outcome data
Informative missingness OR
OR for allocation (95% CI)
MiQuit arm only Control arm only Both arms
0.0 1.13 (0.70–1.83) 1.13 (0.70–1.83) 1.13 (0.70–1.83)
0.2 1.32 (0.80–2.18) 1.01 (0.63–1.60) 1.17 (0.72–1.90)
0.4 1.50 (0.89–2.52) 0.91 (0.58–1.42) 1.20 (0.74–1.95)
0.6 1.68 (0.99–2.87) 0.83 (0.53–1.28) 1.23 (0.75–1.99)
0.8 1.85 (1.07–3.20) 0.76 (0.50–1.17) 1.24 (0.77–2.02)
1.0 2.03 (1.16–3.53) 0.71 (0.46–1.07) 1.26 (0.78–2.05)

















0/466 (0.00%) 3/464 (0.65%) –a −0.65% (−1.38%–0.08%) 0.25 (0.01–1.95) −2.04% (−5.07%–1.00%)
Fetal death 9/473 (1.90%) 15/470 (3.19%) 0.59 (0.25–1.36) −1.29% (−3.30%–0.72%) 0.54 (0.23–1.21) −2.17% (−5.01%–0.66%)
aUndefined because of’ the absence of recorded cases of stillbirth in the MiQuit group.
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interest in receiving information about stopping smoking, increases
prolonged cessation rates in pregnancy compared with UC. There is
also little evidence that MiQuit affects pregnancy outcomes. How-
ever, women randomised to MiQuit, reported smoking fewer ciga-
rettes and were more likely to report at least one quit attempt;
additionally, modelling suggested that, if MiQuit demonstrated only
minimal efficacy, the text message programme could prove highly
cost-effective.
Rates of trial missing outcome data are a potential weakness.
Despite repeated attempts, 26.5% of participants could not be con-
tacted at first follow up, and 35.5% could not in late pregnancy; at
both follow ups, 5% to 6% fewer intervention group participants
responded. Researchers who contacted participants were masked to
study allocations, therefore, different response rates are more likely
because of participant behaviour. The greater number of text message
contacts made to intervention group women may have made some
less likely to respond to follow up calls. However, we assumed those
lost to follow up were smoking, a likely conservative assumption given
that there was more missing outcome data in the MiQuit group. Fur-
thermore, sensitivity analyses suggested reasonably implausible
assumptions regarding the unobserved abstinence data would be
required before the primary analysis reached substantively different
conclusions, a phenomenon documented by others [41]. Additionally,
although we validated 70.4% of abstinence reports and, may have not
identified some participants with positive outcomes, there was little
evidence that trial groups had different rates of ‘failed’ validation
therefore, it seems unlikely that this issue invalidates the principal
findings.
Study strengths include the robust assessment of unforeseen
potential harms, potential generalisability of findings and study size.
Pregnancy outcomes were obtained for 93% of participants and, to
our knowledge; this is the largest and most comprehensive evaluation
of a text message programme for smoking cessation in pregnancy.
One would not expect MiQuit to impact adversely on pregnancy out-
comes and, no such effect was found. Because the trial recruited from
routine antenatal care settings, MiQuit was delivered as an adjunct to
UC and around one-quarter of eligible women joined the trial, study
findings are probably generalizable to women attending routine UK
antenatal care. Additionally, the MiQuit3 RCT recruited 46% more
participants than was originally envisaged in the study sample size cal-
culation, and was the final component in an evaluation that included
economic and trial sequential analyses therefore, a false negative find-
ing is unlikely.
A Cochrane review found ‘moderate-certainty evidence’ that
automated text message interventions promote prolonged smoking
abstinence [42]. Only one study from this review enrolled pregnant
women and this reported a relative risk (95% CI) for 30-day absti-
nence because of the ‘Quit4Baby’ text intervention of 1.34 (1.09–
1.64) [43]. One simple explanation for MiQuit3 trial findings is that
MiQuit is not effective or, at least, not as effective as the impact we
sought to demonstrate. However, because this is a cheap and accept-
able intervention [44] and it is difficult to see how it would cause













10/464 (2.16%) 9/455 (1.98%) 1.09 (0.44–2.71) 0.18% (−1.66%–2.02%) 1.07 (0.44–2.63) 0.23% (−2.71%–3.17%)
Infant ICU
admission




54/464 (11.64) 62/455 (13.63) 0.83 (0.57–1.23) −1.99% (−6.28%–2.31%) 0.86 (0.58–1.27) −1.78% (−6.32%–2.76%)
T AB L E 7 Continuous pregnancy outcomes
Outcome MiQuit Control Unadjusted (95% CI) Adjusted difference (95% CI)
Birth Weight (kg) n 464 455 0.06 (−0.02–0.13) 0.05 (−0.03–0.12)
Mean (SD) 3.1 (0.6) 3.0 (0.6)
Median (Q1, Q3), Min, max 3.1 (2.7, 3.5), 0.6, 4.8 3.1 (2.7, 3.5), 0.7, 4.5
Gestational age at birth (weeks) 0.16 (−0.12–0.44) 0.12 (−0.16–0.40)
n 464 455
Mean (SD) 38.7 (2.0) 38.5 (2.3)
Median (Q1, Q3) 39.0 (37.8, 40.0) 39.0 (37.7, 40.0)
Min, max 27.9, 42.1 26.1, 42.3
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harm, it is reasonable to consider why text messaging used for
smoking cessation in other studies and particularly by non-pregnant
quitters appears more effective. Almost all Cochrane review studies
advertised for participants, therefore, those enrolled are more likely to
have been motivated for cessation [42]. Some study procedures may
also have selected out motivated people as participants. For example,
in the ‘txt2stop’ RCT, participants had to agree to a quit date before
enrolling [45] and in the ‘Quit4Baby’ RCT, 508 participants were rec-
ruited from 35 957 United States (US) women signed up to an antena-
tal health text information service [43]; one would expect more
strongly cessation-motivated women to have joined that trial too. In
contrast, 25.3% of eligible women participated in MiQuit3; they could
join if they agreed to receive information about stopping and they
were not required to set quit dates. Hence, it is plausible that, partici-
pants in this and earlier MiQuit trials would have less motivation to
quit, an observation that may partially explain the smaller treatment
effects found in the MiQuit3 trial compared with other RCTs of simi-
lar text interventions.
We found no evidence that MiQuit offered as an adjunct to UC
results in a 3.4% or more increase in prolonged cessation by pregnant
women, and, our studies also do not rule out MiQuit having a smaller,
but clinically effective impact on cessation. Because MiQuit is a very
cheap intervention the low, albeit imprecise, incremental cost per
QALY estimate suggests that, with only a slightly larger treatment
effect than the 0.6% difference in quit rates found in the MiQuit3
RCT, MiQuit would very likely prove cost-effective and cost saving to
healthcare providers. In all MiQuit studies, the text message pro-
gramme was offered to women who simply agreed to receive informa-
tion on stopping smoking and this was aimed at both encouraging
quitting (‘cessation-induction’) and helping women succeed in quit
attempts (‘aid-to-cessation’). Given the successful way text message
systems have been used in trials, which have reported since MiQuit
was developed, it would be logical to test MiQuit as an ‘aid to cessa-
tion’, offered only to pregnant women who are motivated to try stop-
ping and who agree to set quit dates. MiQuit users reported positive
changes in smoking behaviours and the imprecise point estimates in
treatment effects for causing shorter durations of abstinence than
measured by the primary outcome were overwhelmingly in a positive
direction. Hence, it is plausible, that if MiQuit were to be used by only
motivated quitters, as a cessation aid, it would have more pronounced
effects. Because most pregnant women try stopping soon after con-
ception [9], any effects could be maximised by offering MiQuit earlier
in pregnancy than was possible in the MiQuit3. Because women’s
motivation to quit may fluctuate in pregnancy, the effect of text mes-
sage support might be further increased by adapting messages to
these fluctuations.
Because it is implausible that text systems like MiQuit could harm
pregnant women or babies, and these have such potential for cost
effectiveness through minor impacts on smoking behaviours, further
studies testing MiQuit or similar texted cessation programmes in ways
suggested above are required. However, even RCTs testing intensive
behavioural and pharmacological cessation interventions for pregnant
women can have difficulty demonstrating prolonged abstinence
periods. This is probably because such RCTs have generally recruited
women after 12 weeks of pregnancy and trials’ participants include
women who have not managed, or perhaps not even tried to stop
smoking by then [15,46] and some participants might be less able or
less motivated to stop smoking than pregnant women in general. To
robustly detect very small differences in prolonged smoking cessation
rates would require substantial resources. Our TSA sensitivity analysis
showed that, to detect 2% quit rate difference, 2062 more RCT par-
ticipants’ data would need adding to the TSA meta-analysis. Perhaps
future evaluations of texted cessation programmes should consider
using outcomes that are proxies for prolonged cessation, but which
are indicative of positive behavioural change? For example, shorter
abstinence periods, or the proportion of participants making cessation
attempts could be primary outcomes in RCTs of texted cessation
programmes. Shorter abstinence periods have been demonstrated as
important for fetal health [47], and in both non-pregnant people
[48,49] and in pregnant women [50], quit attempts prompted by
health professionals lead to cessation. Despite the massive impact of
smoking in pregnancy, there are few evidence-based treatment
options for pregnant women; therefore, it is imperative that all inter-
ventions that display positive signals of effect are thoroughly
evaluated.
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